DMTS is an effective treatment in both inhalation and injection models for cyanide poisoning using unanesthetized mice.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model (non-human experiment)
PubMed 28922956 · doi:10.1080/15563650.2017.1376749
What was done
Researchers tested a new formulation of dimethyl trisulfide (DMTS) administered via intramuscular injection as a countermeasure in unanesthetized mice exposed to lethal doses of cyanide. The evaluation included a subcutaneous potassium cyanide (KCN) injection model and nose-only hydrogen cyanide (HCN) inhalation models with both continuous (10-minute) and discontinuous (40-minute) exposure paradigms at LC50 doses.
What was found
In the KCN injection model, DMTS treatment protected mice against 3.73 times the LD50 dose. In the inhalation models, mice challenged with LC50 doses of HCN achieved 87.5% survival in the 10-minute exposure paradigm and 90.0% survival in the 40-minute exposure paradigm following DMTS treatment, along with improvements in observed signs of toxicity.
Why it matters
Inhaled cyanide exposure represents a rapid and lethal threat requiring quickly deliverable countermeasures; these findings support intramuscular DMTS as a potential field-deployable antidote formulation.
Limits
The study was conducted entirely in mice, limiting direct translation of pharmacokinetics and efficacy to humans. The abstract does not report total sample sizes, exact timing of post-exposure antidote administration, comparator antidotes, or quantitative statistical dispersion metrics.
Cited by
- supports Cyanide causes rapid death by binding to proteins involved in aerobic respiration and shutting down oxidative phosphorylation.